AR002702A1 - Formulación farmacéutica oral estable conteniendo un compuesto de bencimidazol labil en medio ácido su procedimiento de obtención y sus formulaciones galenicas - Google Patents

Formulación farmacéutica oral estable conteniendo un compuesto de bencimidazol labil en medio ácido su procedimiento de obtención y sus formulaciones galenicas

Info

Publication number
AR002702A1
AR002702A1 AR10105196A AR10105196A AR002702A1 AR 002702 A1 AR002702 A1 AR 002702A1 AR 10105196 A AR10105196 A AR 10105196A AR 10105196 A AR10105196 A AR 10105196A AR 002702 A1 AR002702 A1 AR 002702A1
Authority
AR
Argentina
Prior art keywords
formulation containing
acidic medium
benzimidazole compound
stable oral
obtaining procedure
Prior art date
Application number
AR10105196A
Other languages
English (en)
Spanish (es)
Inventor
Rodes Montserrat Ballester
Boven Marinus Van
Original Assignee
Esteve Quimica Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8289322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR002702(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esteve Quimica Sa filed Critical Esteve Quimica Sa
Publication of AR002702A1 publication Critical patent/AR002702A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AR10105196A 1995-02-01 1996-01-17 Formulación farmacéutica oral estable conteniendo un compuesto de bencimidazol labil en medio ácido su procedimiento de obtención y sus formulaciones galenicas AR002702A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09500181A ES2094694B1 (es) 1995-02-01 1995-02-01 Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.

Publications (1)

Publication Number Publication Date
AR002702A1 true AR002702A1 (es) 1998-04-29

Family

ID=8289322

Family Applications (1)

Application Number Title Priority Date Filing Date
AR10105196A AR002702A1 (es) 1995-02-01 1996-01-17 Formulación farmacéutica oral estable conteniendo un compuesto de bencimidazol labil en medio ácido su procedimiento de obtención y sus formulaciones galenicas

Country Status (20)

Country Link
US (1) US5626875A (instruction)
EP (2) EP0773025B1 (instruction)
JP (1) JP4183746B2 (instruction)
KR (1) KR100331290B1 (instruction)
AR (1) AR002702A1 (instruction)
AT (2) ATE193649T1 (instruction)
AU (1) AU4540396A (instruction)
CA (1) CA2184842C (instruction)
DE (3) DE69608767D1 (instruction)
DK (2) DK0773025T3 (instruction)
ES (3) ES2094694B1 (instruction)
FI (1) FI121730B (instruction)
HU (1) HU229219B1 (instruction)
IL (1) IL116673A (instruction)
IN (1) IN186596B (instruction)
PT (2) PT773025E (instruction)
SI (2) SI0773025T1 (instruction)
TW (1) TW503115B (instruction)
WO (1) WO1996023500A1 (instruction)
ZA (1) ZA96683B (instruction)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
ES2236628T3 (es) 1995-09-21 2005-07-16 Pharma Pass Ii Llc Composicion farmaceutica que contiene un omeprazol labil de acido, y procedimiento para su preparacion.
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
FR2774288B1 (fr) † 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
ATE526022T1 (de) * 1998-04-20 2011-10-15 Eisai R&D Man Co Ltd Stabilisierte zusammenstellungen die benzimidazole enthalten
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
WO2000009092A1 (en) * 1998-08-12 2000-02-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
TWI268779B (en) 1999-10-20 2006-12-21 Eisai Co Ltd Method for stabilizing benzimidazole-based compounds
DE19959419A1 (de) * 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
DK1108425T3 (da) * 1999-12-16 2005-09-26 Medinfar Produtos Farmaceutico Nye, stabile flerenhedspræparater, der indeholder substituerede benzimidazoler
US6419956B1 (en) 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
KR20030051794A (ko) * 2000-11-10 2003-06-25 에프. 호프만-라 로슈 아게 가수분해에 불안정한 조성물
CA2449175A1 (en) * 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
KR100914175B1 (ko) 2001-07-16 2009-08-27 얀센 파마슈티카 엔.브이. 벤즈이미다졸-타입 화합물의 개선된 제조 방법
EP1438030A2 (en) * 2001-09-28 2004-07-21 McNEIL-PPC, INC. Modified release dosage forms
US20040170689A1 (en) * 2001-11-09 2004-09-02 Odink Debra Alida Stabilized formulations comprising hydrolytically unstable compositions
ES2198195B1 (es) 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
ES2299710T3 (es) * 2002-08-02 2008-06-01 Ratiopharm Gmbh Preparacion farmaceutica que contiene un compuesto de bencimidazol mezclado con celulosa microcristalina y un metodo para su preparacion.
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
WO2004066982A1 (en) * 2003-01-31 2004-08-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and processes for their preparation
MXPA05010819A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
US20040259899A1 (en) * 2003-04-08 2004-12-23 Sanghvi Suketu P. Combination therapy for constipation
HRP20150037T4 (hr) * 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
AU2003245033A1 (en) * 2003-05-08 2004-11-26 Podili Khadgapathi An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation
WO2005011637A1 (ja) * 2003-08-04 2005-02-10 Eisai Co., Ltd. 用時分散型製剤
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005034924A1 (en) * 2003-10-14 2005-04-21 Natco Pharma Limited Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
GB0400781D0 (en) * 2004-01-14 2004-02-18 Novartis Ag Organic compounds
US20050214372A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
PL1746980T3 (pl) 2004-05-07 2012-03-30 Nycomed Gmbh Farmaceutyczna postać dawkowania zawierająca peletki i sposób jej wytwarzania
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
EP1830823A2 (en) 2004-12-23 2007-09-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
MX2007008141A (es) * 2005-01-03 2007-12-10 Lupin Ltd Composicion farmaceutica de sustancias labiles en medio acido.
CN101137378A (zh) * 2005-01-20 2008-03-05 普罗热尼奇制药公司 甲基纳曲酮和相关化合物治疗术后胃肠功能障碍的用途
WO2006087613A2 (en) * 2005-02-02 2006-08-24 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions prepared by non-aqueous layering process
EP1861096B1 (en) 2005-03-07 2018-12-26 The University of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
EP1785135A1 (en) * 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. New stabilized galenic formulations comprising lansoprazole and their preparation
CA2633825A1 (en) * 2005-12-20 2007-07-05 Teva Pharmaceutical Industries Ltd. Lansoprazole orally disintegrating tablets
EP1813275A1 (en) * 2005-12-20 2007-08-01 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
ITMI20061024A1 (it) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico
ES2511792T3 (es) * 2006-07-25 2014-10-23 Vecta Ltd. Composiciones y métodos para la inhibición de la secreción de ácido gástrico usando derivados de pequeños ácidos dicarboxílicos en combinación con IBP
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
WO2008121860A1 (en) * 2007-03-29 2008-10-09 Wyeth Peripheral opioid receptor and antagonists and uses thereof
EP3064503A1 (en) * 2007-03-29 2016-09-07 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
CN101801979A (zh) 2007-03-29 2010-08-11 普罗热尼奇制药公司 (r)-n-溴化甲基纳曲酮的晶体形式及其用途
US8471022B2 (en) * 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
US20110250278A1 (en) 2008-07-01 2011-10-13 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
CA2733299A1 (en) * 2008-08-11 2010-02-18 Mepha Gmbh Oral pharmaceutical formulation for omeprazole comprising a specific separation layer
CH699302B1 (de) * 2008-08-11 2012-03-15 Mepha Gmbh Orale pharmazeutische Formulierung für Omeprazol, enthaltend eine spezifische Trennschicht.
CA2676881C (en) * 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2010117756A2 (en) * 2009-03-31 2010-10-14 Dr. Reddy's Laboratories Ltd Substituted benzimidazole pharmaceutical formulations
US20130202688A1 (en) 2010-05-04 2013-08-08 Sunilendu Bhushan Roy Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
BR112014009580B1 (pt) * 2011-11-02 2022-03-29 Esteve Pharmaceuticals, S.A Composição farmacêutica de omeprazol
GB2513172A (en) * 2013-04-18 2014-10-22 Nupharm Lab Ltd Liquid dosage form and delivery system
WO2016061531A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3292862A1 (en) 2016-09-07 2018-03-14 Sandoz Ag Omeprazole formulations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB829055A (en) * 1958-02-07 1960-02-24 Charles E Frosst And Company Improvements in or relating to pharmaceutical preparations
US4150111A (en) * 1974-05-28 1979-04-17 Allister Warren Enteric coated magnesium chloride
JPS5837285B2 (ja) * 1975-05-29 1983-08-15 カブシキガイシヤ ミドリジユウジ チヨウナイカンセンシヨウチリヨウザイノセイゾウホウホウ
JPS5598120A (en) * 1979-01-16 1980-07-25 Shin Etsu Chem Co Ltd Preparation of drug having enteric coating
US4470980A (en) * 1980-03-07 1984-09-11 Interx Research Corp. Method of increasing oral absorption of β-lactam antibiotics
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
JPS58208155A (ja) * 1982-05-28 1983-12-03 Sumitomo Electric Ind Ltd 光伝送用ガラスフアイバの製造方法
JPS59193831A (ja) * 1983-04-18 1984-11-02 Sankyo Co Ltd 腸溶性製剤の製造法
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US5395611A (en) * 1990-04-24 1995-03-07 The Governors Of The University Of Alberta Phenolic amine depigmenting and antimelanoma agents
IT1241740B (it) * 1990-06-22 1994-02-01 Edi Bondioli Protezione per una forcella di estremita' di un albero cardanico
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
ATE156707T1 (de) * 1991-06-21 1997-08-15 Ilsan Ilac Ve Hammaddeleri San Neues galenisches verfahren für omeprazol enthaltende pellets
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
WO1994002140A1 (en) * 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process

Also Published As

Publication number Publication date
DE69608767D1 (de) 2000-07-13
DK0773025T3 (da) 2000-10-09
PT773025E (pt) 2000-10-31
ES2094694B1 (es) 1997-12-16
FI121730B (fi) 2011-03-31
ATE193649T1 (de) 2000-06-15
ES2148725T3 (es) 2000-10-16
JPH09511257A (ja) 1997-11-11
TW503115B (en) 2002-09-21
HUP9603014A3 (en) 2000-12-28
EP0993830B1 (en) 2005-04-13
EP0773025A1 (en) 1997-05-14
EP0993830A2 (en) 2000-04-19
ES2238796T3 (es) 2005-09-01
EP0773025B1 (en) 2000-06-07
IN186596B (instruction) 2001-10-06
WO1996023500A1 (es) 1996-08-08
IL116673A (en) 2000-10-31
DK0993830T3 (da) 2005-08-08
EP0993830A3 (en) 2001-10-04
DE69634613D1 (de) 2005-05-19
IL116673A0 (en) 1996-05-14
CA2184842A1 (en) 1996-08-08
SI0993830T1 (en) 2005-10-31
CA2184842C (en) 2007-08-07
US5626875A (en) 1997-05-06
PT993830E (pt) 2005-06-30
DE29623938U1 (de) 2000-10-05
AU4540396A (en) 1996-08-21
DE69634613T2 (de) 2006-03-09
KR100331290B1 (ko) 2002-11-22
ZA96683B (en) 1997-09-23
HUP9603014A2 (hu) 1998-03-30
ATE292967T1 (de) 2005-04-15
SI0773025T1 (en) 2000-10-31
ES2094694A1 (es) 1997-01-16
FI963916L (fi) 1996-09-30
JP4183746B2 (ja) 2008-11-19
HU229219B1 (en) 2013-09-30
FI963916A0 (fi) 1996-09-30

Similar Documents

Publication Publication Date Title
AR002702A1 (es) Formulación farmacéutica oral estable conteniendo un compuesto de bencimidazol labil en medio ácido su procedimiento de obtención y sus formulaciones galenicas
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
DE69621885D1 (de) Neue galenische orale pharmazeutische formulierung
TR199901077A3 (tr) Ispençiyari formülasyonlar.
DE69525148D1 (de) Pharmazeutische formulierung
ID24654A (id) Formulasi farmasi omeprazola
DK1001813T3 (da) Farmaceutiske formuleringer indeholdende voriconazol
ATE228823T1 (de) Pharmazeutische aerosolformulierung
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
NO974363L (no) Oral 2-metyl-thieno-benzodiazepinformulering
DZ2686A1 (fr) Formulation pharmaceutique orale à libération pulsée.
EE04002B1 (et) Peroraalne farmatseutiline annusvorm, mis sisaldab prootonpumba inhibiitorit ja antatsiidainet või alginaati
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
NO20012915D0 (no) Ny farmasöytisk formulering
ATE312602T1 (de) Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
DZ2055A1 (fr) Compositions vaccinantes.
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
NO993096D0 (no) Orale cyklosporinformuleringer
DE69822172D1 (de) Levosimendanhaltige oral anzuwendende arzneizusammensetzungen
EE05375B1 (et) LevosimendaniÁfarmatseutilineÁlahus
DE69807768D1 (de) Rapamycin enthaltende Formulierungen zur oralen Verabreichung
TR199501082A2 (tr) Farmasötik formülasyonlar.
ATE295150T1 (de) Pharmazeutische zusammensetzungen
DE69708130D1 (de) A-oxo-butansäuren enthaltende pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
FC Refusal